ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

BAG3 Mutation Associated Dilated Cardiomyopathy

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Research Site, Birmingham, Alabama, United States
Contact: Study coordinator (Nehal Vekariya) · nvekariya@uabmc.edu · 205-934-7173
Research Site, Boston, Massachusetts, United States
Contact: Study coordinator (Alyx Vogle) · avogle@bwh.harvard.edu · 617-732-6320
Research Site, Cincinnati, Ohio, United States
Contact: Study coordinator (Michael Weber) · michael.weber@thechristhospital.com · 513-585-1777
Research Site, Portland, Oregon, United States
Contact: Study coordinator (Hailey Volk) · volkh@ohsu.edu · 503-418-2246
Research Site, Philadelphia, Pennsylvania, United States
Contact: Study coordinator (Joseph Puhl) · joseph.puhl@pennmedicine.upenn.edu · 267-399-3049
Research Site, Houston, Texas, United States
Contact: Study coordinator (Jennifer Garrett) · 346-238-4516
Research Site, Massa, Italy
Research Site, Barcelona, Spain
Research Site, Majadahonda, Spain
Research Site, London, United Kingdom

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

An AAV Gene Therapy Trial of AFTX-201 in Adults With BAG3-Associated Dilated Cardiomyopathy (DCM)

Dilated Cardiomyopathy (DCM) · BAG3 Mutation Associated Dilated Cardiomyopathy

Abroad (travel likely)RecruitingPHASE1, PHASE2

Miami, United States · Kansas City, United States